Lena Allweiss Selected Research

myrcludex-B

1/2022	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
1/2019	T cell receptor grafting allows virological control of Hepatitis B virus infection.
1/2019	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.
1/2018	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
5/2013	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
3/2012	Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lena Allweiss Research Topics

Disease

22	Infections 06/2022 - 06/2011
6	Viremia 08/2017 - 06/2011
4	Coinfection 01/2019 - 03/2012
3	Reinfection 01/2022 - 01/2018
3	Chronic Hepatitis B 01/2020 - 06/2011
3	Hepatitis B 01/2019 - 03/2012
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 01/2019
1	Focal Nodular Hyperplasia 01/2019
1	Chronic Hepatitis (Chronic Active Hepatitis) 05/2016
1	Virus Diseases (Viral Diseases) 05/2016
1	Persistent Infection 04/2016
1	Liver Diseases (Liver Disease) 08/2015
1	Inflammation (Inflammations) 08/2015
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2014

Drug/Important Bio-Agent (IBA)

8	Antiviral Agents (Antivirals)IBA 06/2022 - 06/2011
6	myrcludex-BIBA 01/2022 - 03/2012
6	RNA (Ribonucleic Acid)IBA 01/2019 - 06/2011
5	Circular DNAIBA 01/2022 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2013
3	Hepatitis delta Antigens (HDAg)IBA 01/2019 - 03/2012
3	InterferonsIBA 01/2018 - 06/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 05/2013
3	AntigensIBA 01/2017 - 05/2013
2	sodium-bile acid cotransporterIBA 01/2021 - 01/2019
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 01/2017
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 08/2017
2	entecavir FDA Link 01/2018 - 01/2017
2	NucleosidesIBA 01/2018 - 01/2012
2	Interferon-alpha (Interferon Alfa)IBA 01/2017 - 03/2014
2	Hepatitis B Core AntigensIBA 01/2017 - 05/2013
2	Pharmaceutical PreparationsIBA 05/2016 - 03/2012
2	LipopeptidesIBA 05/2013 - 03/2012
1	Toll-Like Receptor 2IBA 01/2020
1	NVR 3-778IBA 01/2018
1	Messenger RNA (mRNA)IBA 08/2017
1	Hepatitis B virus P proteinIBA 01/2017
1	AntibodiesIBA 05/2016
1	VaccinesIBA 04/2016
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2014
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2014
1	Peptides (Polypeptides)IBA 03/2012
1	NucleotidesIBA 01/2012

Therapy/Procedure

6	Therapeutics 06/2022 - 06/2011
1	Injections 08/2017
1	Intravenous Injections 05/2016
1	Liver Transplantation 03/2014
1	Aftercare (After-Treatment) 05/2013